Articles

Selinexor in combination with standard induction and consolidation therapy appears highly active in older patients with de novo acute myeloid leukemia. Read More ›

This first-in-human study indicates that CLL1-CD33 cCAR has favorable efficacy and manageable toxicity in patients with R/R AML. Read More ›

The combination of dabrafenib and trametinib performs as well in the real world as in clinical trials in patients with BRAF V⁶⁰⁰-mutated advanced melanoma and brain metastases, but the medical need for patients with brain metastases remains high. Read More ›

The combination of ipilimumab and anti–PD-1 therapy showed efficacy comparable to clinical trial populations in patients with preexisting autoimmune disease and advanced melanoma. Read More ›

A review of posts to health-related social media over a 5-year period reveals that symptoms and their impact are the most frequently discussed topics by patients with melanoma and their caregivers. Read More ›

In a landmark single-institution analysis of patients with advanced melanoma, those who stopped their immunotherapy within 7 months of achieving a complete response had comparable disease-free survival to those who were treated for longer than 7 months. Read More ›

Real-world analysis suggests that ipilimumab/nivolumab should be considered over a single-agent PD-1 inhibitor for metastatic melanoma, regardless of BRAF status. Read More ›

Read More ›

Read More ›

Read More ›